DRG Market Assessment reports

Peripheral arterial disease (PAD) is a complex manifestation of underlying atherosclerotic disease and is severely undertreated. The failure of therapies to improve walking distance or reduce…

Fibromyalgia is a complex disease that is difficult to treat because of patient heterogeneity, frequent comorbid conditions, and numerous symptoms, including pain, depression, fatigue, and sleep…

Payers play a significant role in defining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…

A variety of analgesic products are available to specialists managing postoperative pain in the United States, although the majority of these medicines are available as inexpensive generics…

Celltrion’s Herzuma was the first biosimilar of Roche’s Herceptin, a blockbuster HER2-targeted therapy, to launch in Europe. A few months later, three additional trastuzumab biosimilars…

Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for NHL…

MARKET OUTLOOK Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has globally the highest number of RA patients, and the Chinese…

MARKET OUTLOOK NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of…

MARKET OUTLOOK Pancreatic cancer is a life-threatening disease with a survival rate of less than 10% and with no improvements in the last 40 years. Owing to the lack of rapid diagnostics, the…

MARKET OUTLOOK The lucrative HR-positive, HER2-negative breast cancer market in Europe is fast-moving and competitive. CDK4/6 inhibitors Ibrance (Pfizer), Kisqali (Novartis) and Verzenios (Eli…

MARKET OUTLOOK The European atopic dermatitis (AD) market has entered a new era. In 2017, IL-4/13 inhibitor Dupixent (Sanofi/Regeneron) became the first targeted biologic to be approved for…

With the launch of four adalimumab biosimilars into the European market in October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), and Hyrimoz (Sandoz)—competition within the already…